Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining ... and that counterfeit forms of Ozempic are being sold. Semaglutide and a similar GLP-1 drug, ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...

Sahpra warns against counterfeit GLP-1 products like Ozempic, citing health risks. Only registered products should be used; ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...

Sahpra warns of falsified diabetes treatments Ozempic and Mounjaro sold online for weight loss, posing health risks.

In recent health news, Chinese scientists stress the need for regional diets to combat obesity, U.S. minority veterans ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...